What Wall St. Knows About Teva Pharmaceutical Industries Today.

Large-cap Health Care company Teva Pharmaceutical Industries has logged a -4.0% change today on a trading volume of 7,747,583. The average volume for the stock is 9,453,428.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. Based in Tel Aviv, Israel the company has 34,004 full time employees and a market cap of $9,605,855,232.

The company is now trading -18.84% away from its average analyst target price of $10.56 per share. The 9 analysts following the stock have set target prices ranging from $8.0 to $14.0, and on average give Teva Pharmaceutical Industries a rating of hold.

Over the last 52 weeks, TEVA stock has risen 8.0%, which amounts to a -14.0% difference compared to the S&P 500. The stock's 52 week high is $11.45 whereas its 52 week low is $7.09 per share. Based on Teva Pharmaceutical Industries's average net margin growth of 22.5% over the last 6 years, its core business is on track for profitability and its strong stock performance may continue in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023-02-10 14,925,000 -2,353,000 -16 -633.33
2022-02-09 15,878,000 416,000 3 112.5
2021-02-10 16,659,000 -3,990,000 -24 -300.0
2020-02-21 16,887,000 -999,000 -6 50.0
2019-02-19 18,271,000 -2,150,000 -12 83.56
2018-02-01 22,385,000 -16,265,000 -73
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS